Climb Bio, Inc. (CLYM) compared with its closest peers (CGEM, VERA, ZBIO, KYTX, ACET). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Cullinan Therapeutics and Vera Therapeutics: named as a competitor in the 10-K; Zenas BioPharma, Kyverna Therapeutics and Cabaletta Bio: named a competitor in the 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $1.32B | — |
| Vera Therapeutics, Inc. (VERA) | $2.52B | — |
| Zenas BioPharma, Inc. (ZBIO) | $1.97B | — |
| Kyverna Therapeutics, Inc. (KYTX) | $448.98M | — |
| Adicet Bio, Inc. (ACET) | $89.00M | — |
| Cabaletta Bio, Inc. (CABA) | $463.71M | — |
| Contineum Therapeutics, Inc. (CTNM) | $554.52M | — |
| Precigen, Inc. (PGEN) | $2.45B | — |
| Crinetics Pharmaceuticals, Inc. (CRNX) | $9.01B | — |
| Bolt Biotherapeutics, Inc. (BOLT) | $7.40M | — |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
CLYM overview · CLYM earnings · CLYM financials · CLYM KPIs · CLYM documents · CLYM ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.